Abstract
Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Current Pharmaceutical Design
Title:Brain Targeting of siRNA via Intranasal Pathway
Volume: 21 Issue: 31
Author(s): Chandana Mohanty, Paromita Kundu and Sanjeeb K. Sahoo
Affiliation:
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Abstract: Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Export Options
About this article
Cite this article as:
Mohanty Chandana, Kundu Paromita and Sahoo K. Sanjeeb, Brain Targeting of siRNA via Intranasal Pathway, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191737
DOI https://dx.doi.org/10.2174/138161282131151013191737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Behavioral Decision Research Intervention Reduces Risky Sexual Behavior
Current HIV Research Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Does Piperacillin-Tazobactam Increase the Risk of Nephrotoxicity when Used with Vancomycin: A Meta-Analysis of Observational Trials
Current Drug Safety Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression
Current Cancer Drug Targets Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
Current Medicinal Chemistry Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Undressing the Fungal Cell Wall/Cell Membrane - the Antifungal Drug Targets
Current Pharmaceutical Design